重大事件
即時報告
8-K
2026-07-02
RenovoRx獲Nasdaq第二合規期 延至2026年底達1美元門檻
AI 繁中摘要
8-K 申報 | 2026年7月1日事件
RenovoRx, Inc.（納斯達克代碼：RNXT）於2026年7月1日提交8-K，披露獲得納斯達克第二個合規期。此前公司在2025年12月31日收到Nasdaq通知，因其普通股收盤買入價連續低於1美元，未能符合Nasdaq資本市場持續上市的最低買入價要求（Nasdaq上市規則第5550(a)(2)條）。首個合規期原定於2026年6月30日屆滿。
2026年7月1日，Nasdaq書面通知RenovoRx，雖然尚未恢復合規，但公司符合資格獲得額外180天合規期（「第二合規期」），即延長至2026年12月28日。若第二合規期內任何時間，普通股收盤買入價至少連續10個交易日達到或超過1美元，Nasdaq將書面確認合規。若未能於2026年12月28日前證明合規，Nasdaq將發出退市通知，屆時公司可向聽證會小組提出上訴。📉
對投資者的潛在影響：RenovoRx 獲得近六個月緩衝期，有機會透過股價表現或採取行動（如股份合併）來滿足1美元最低買入價要求。若最終未能合規，普通股將面臨從納斯達克退市的風險，可能影響流動性及股價。公司需積極管理股價及與Nasdaq溝通，投資者宜留意後續合規進展。⚠️
展開英文正文
false 0001574094 0001574094 2026-07-01 2026-07-01 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 1, 2026 RENOVORX, INC. (Exact name of registrant as specified in its charter) Delaware 001-40738 27-1448452 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.) 2570 W El Camino Real, Suite 640 Mountain View, CA 94040 (Address of principal executive offices) (Zip Code) Registrant’s telephone number, including area code: (650) 284-4433 N/A (Former name or former address, if changed since last report.) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below): ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $0.0001 par value per share RNXT Nasdaq Capital Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☒ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. As previously reported, on December 31, 2025, RenovoRx, Inc., a Delaware corporation (the “Company”) received a deficiency notice from The Nasdaq Stock Market (“Nasdaq”) informing the Company that its common stock (the “Common Stock”) had failed to comply with the $1.00 minimum bid price required for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”). Pursuant to Nasdaq Listing Rule 5810(c)(3)(A), the Company was initially provided 180 calendar days, or until June 30, 2026, to regain compliance. On July 1, 2026, the Company received a notification letter from Nasdaq informing the Company that, while the Company has not yet regained compliance with the Minimum Bid Price Requirement, Nasdaq has determined that the Company is eligible for an additional 180 calendar day period, or until December 28, 2026 (the “Second Compliance Period”), to regain compliance. If at any time during the Second Compliance Period, the closing bid price of the Common Stock is at least $1.00 per share for a minimum of 10 consecutive business days, Nasdaq will provide the Company with written confirmation of compliance. If compliance with the Minimum Bid Price Requirement cannot be demonstrated by December 28, 2026, Nasdaq will provide written notification that the Common Stock will be delisted from Nasdaq. At that time, the Company may appeal Nasdaq’s determination to a Hearings Panel. SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. RenovoRx, Inc. Date: July 2, 2026 By: /s/ Shaun R. Bagai Name: Shaun R. Bagai Title: Chief Executive Officer